Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa

Figure 1

Mean BCVA improvement after dexamethasone implant in anti-VEGF refractory eyes was 4 letters ((a) change in logMAR 0.42 to 0.36, ); treatment naïve eyes gained 10 letters after dexamethasone implant ((b) change in logMAR 1.07 to 0.82, ), while we noted no significant change in eyes refractory to dexamethasone implant after switch to anti-VEGF ((c) change in logMAR 0.55 to 0.52, ). A = BCVA before switch from anti-VEGF to dexamethasone (a) or vice versa (c) or before treatment (b); B = best BCVA after switch/treatment at 88 days [70; 176], 92 days [87; 100], and 123 days [96; 210]; and C = at the end of observation (median follow-up was 4.3 months for the Anti-VEGF_Dexamethasone group, 3.1 months for the Dexamethasone group, and 6.0 months for the Dexamethasone_anti-VEGF group).